| Today’s Big NewsJan 24, 2024 |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
| By Gabrielle Masson Eli Lilly says an investigational gene therapy has restored hearing in one child who has experienced hearing loss since birth. |
|
|
|
By Angus Liu The FDA’s letter demanding a labeling change for Gilead Sciences’ Tecartus temporarily went missing on the agency’s website Tuesday. Turns out, the FDA didn’t drop the CD19 CAR-T from a classwide safety alert list. Instead, it's adjusted the wording of a proposed boxed warning. |
By Andrea Park Last year's increase easily outstripped not only the “high single-digit” rate Abbott had predicted at the start of the year, but also the 7% growth rate it had posted in the two years leading up to 2020. |
By Nick Paul Taylor A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer. |
By Fraiser Kansteiner Shortly after its spinoff and IPO, WuXi Biologics’ subsidiary WuXi XDC has locked up a major customer on its quest to establish itself as a premier bioconjugation contract research, development and manufacturing organization. |
By Fraiser Kansteiner Apotex and two of its generics peers have agreed to settle with direct purchasers of their drugs in a price-fixing case that stretches all the way back to 2017. |
By Max Bayer BenevolentAI has named longtime pharma exec Joerg Moeller as its new CEO. He previously led R&D at LEO Pharma after nearly two decades at Bayer. |
By Conor Hale After announcing last September that it had logged the first successful implantation of its pea-sized neurostimulator for depression, Motif Neurotech has raised $18.75 million in VC funds. |
By Conor Hale CardioSignal, the developers of an app that performs a heart test using some of the most basic smartphone features, has collected $10 million in early venture capital funding to validate its approach in the clinic. |
By Joseph Keenan Pharma giant GSK and Elegen are partnering to leverage the California-based DNA manufacturer's proprietary technology to help develop new vaccines and medicines. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Sofia Guerra and Steve Kraus from Bessemer Venture Partners sat down with Fierce Healthcare's Heather Landi to discuss the health tech sector's performance, unraveling the factors that contributed to its current state. They share what it will take to get health tech out of its current market lull and explore whether we’ll see a rebound in IPOs this year. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
